LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

Home・Lista de Ações・Design Therapeutics Inc

Design Therapeutics Inc

Abrir

10.22 -2.94

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.87

Máximo

10.69

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -18M
EPS	-0.29
Funcionários	54
EBITDA	-1.5M -20M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+87.02% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-115M 685M
Abertura anterior	13.16
Fecho anterior	10.22

Design Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 de jun. de 2026, 23:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 de jun. de 2026, 23:37 UTC

Conversa de Mercado

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 de jun. de 2026, 23:01 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 de jun. de 2026, 23:01 UTC

Conversa de Mercado

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 de jun. de 2026, 22:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 de jun. de 2026, 22:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 de jun. de 2026, 22:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 de jun. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 de jun. de 2026, 21:53 UTC

Conversa de Mercado

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 de jun. de 2026, 21:22 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

1 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

1 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

1 de jun. de 2026, 20:46 UTC

Aquisições, Fusões, Aquisições de Empresas

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 de jun. de 2026, 20:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Array Digital Infrastructure Declares $11 Special Div

1 de jun. de 2026, 20:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 de jun. de 2026, 19:40 UTC

Conversa de Mercado

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 de jun. de 2026, 19:28 UTC

Conversa de Mercado

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 de jun. de 2026, 19:01 UTC

Conversa de Mercado

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 de jun. de 2026, 18:58 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 de jun. de 2026, 18:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 de jun. de 2026, 18:33 UTC

Conversa de Mercado

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 de jun. de 2026, 18:32 UTC

Conversa de Mercado

Precious Metals Fall to Start June -- Market Talk

1 de jun. de 2026, 18:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 de jun. de 2026, 17:18 UTC

Conversa de Mercado

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 de jun. de 2026, 17:18 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 de jun. de 2026, 17:10 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparação entre Pares

Variação de preço

Design Therapeutics Inc Previsão

Preço-alvo

By TipRanks

87.02% parte superior

Previsão para 12 meses

Média 19.6 USD 87.02%

Máximo 22 USD

Mínimo 15 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Design Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Design Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.